Delivery Order SPE2DB20D3505-SPE2DB25FV1L2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $54,946.51 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 3, 2025, with an ultimate completion date of July 7, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $7,112.21 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed price order represents a single delivery transaction under AmerisourceBergen's larger contract vehicle with DLA. The contract was executed on September 8, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections valued at $13,018.75 under a firm fixed-price contract. The delivery order, which concludes on September 11, 2025, represents a competitively awarded non-set-aside procurement supporting the federal government's pharmaceutical supply requirements. The contract will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $19,398.30 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This is a firm fixed price, non-set-aside contract with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase under AmerisourceBergen's larger contract vehicle with...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $5,537.88 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed price contract, issued without a set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $79,739.95 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors (2 ml units) on July 15, 2025, with completion expected by July 16, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $10,503.00 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors. This competitively awarded, firm fixed-price contract was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and will be performed in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's capability to compete openly for federal pharmaceutical procurement...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FV1L2Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,979.13 for Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price contract, which has no set-aside designation, represents a competitively awarded procurement supporting federal medical supply needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and running through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. Dupixent, a specialty pharmaceutical treatment for inflammatory conditions, exemplifies the range of brand-name medications the contractor delivers through this strategic partnership supporting defense healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.0k | 8/7/25 |